3,041 Shares of Cencora, Inc. $COR Acquired by Krilogy Financial LLC

Krilogy Financial LLC purchased a new stake in Cencora, Inc. (NYSE:COR) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 3,041 shares of the company’s stock, valued at approximately $913,000.

Other large investors also recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of Cencora in the 2nd quarter worth approximately $5,154,136,000. T. Rowe Price Investment Management Inc. raised its holdings in shares of Cencora by 160.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock worth $2,262,956,000 after purchasing an additional 4,123,795 shares in the last quarter. Bank of America Corp DE lifted its stake in Cencora by 6.9% during the first quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock valued at $1,300,033,000 after purchasing an additional 267,318 shares during the last quarter. Amundi lifted its stake in Cencora by 43.5% during the second quarter. Amundi now owns 2,229,326 shares of the company’s stock valued at $630,855,000 after purchasing an additional 676,066 shares during the last quarter. Finally, Carmignac Gestion lifted its stake in Cencora by 58.7% during the second quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock valued at $494,463,000 after purchasing an additional 646,112 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president owned 19,455 shares in the company, valued at $6,305,754.60. This represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.38% of the company’s stock.

Cencora Trading Down 0.3%

Shares of Cencora stock traded down $0.87 during trading on Friday, hitting $340.54. The stock had a trading volume of 1,978,868 shares, compared to its average volume of 1,282,490. The stock has a 50 day simple moving average of $320.38 and a 200 day simple moving average of $303.34. The company has a market capitalization of $64.99 billion, a PE ratio of 25.30, a P/E/G ratio of 1.75 and a beta of 0.58. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.35 by $0.13. The business had revenue of $84.75 billion for the quarter, compared to analyst estimates of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The firm’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.00 earnings per share. On average, research analysts expect that Cencora, Inc. will post 17.87 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Friday, August 14th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, August 14th. Cencora’s payout ratio is presently 17.83%.

Analyst Ratings Changes

A number of analysts recently weighed in on COR shares. Evercore restated an “outperform” rating and set a $350.00 target price (up from $330.00) on shares of Cencora in a report on Thursday, August 6th. Morgan Stanley upped their price target on Cencora from $342.00 to $346.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Wells Fargo & Company increased their price objective on Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. raised their price objective on Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Leerink Partners raised their price objective on Cencora from $380.00 to $388.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 7th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $363.81.

Cencora Company Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.